middl
east
respiratori
syndrom
coronaviru
merscov
emerg
highli
fatal
caus
sever
acut
respiratori
infect
sinc
april
case
death
twentyf
countri
attribut
novel
humantohuman
transmiss
viru
sustain
larg
zoonot
reservoir
may
serv
princip
sourc
transmiss
high
case
fatal
rate
vagu
defin
epidemiolog
absenc
prophylact
therapeut
measur
novel
viru
creat
urgent
need
effect
vaccin
outbreak
expand
pandem
proport
past
effort
develop
coronaviru
vaccin
use
wholeinactiv
viru
liveattenu
viru
recombin
protein
subunit
genet
primari
target
neutral
antibodi
spike
glycoprotein
cleav
two
subunit
distal
viru
membran
contain
transmembran
domain
two
heptadrepeat
sequenc
typic
class
fusion
subunit
focu
immun
strategi
contain
receptorbind
domain
rbd
mediat
viru
attach
host
receptor
dipeptidyl
express
rbd
multipl
vaccin
platform
elicit
neutral
antibodi
high
prevent
viral
attach
across
mani
strain
elicit
antibodi
contribut
neutral
fusion
inhibit
develop
altern
vaccin
regimen
base
fulllength
dna
truncat
subunit
glycoprotein
elicit
broad
repertoir
antibodi
divers
mechan
viral
neutral
found
immun
construct
protect
nonhuman
primat
nhp
sever
lung
diseas
intratrach
challeng
merscov
origin
design
five
vaccin
construct
basi
sequenc
merscov
spike
glycoprotein
fig
strain
genbank
id
chosen
basi
avail
sequenc
proxim
consensu
among
publish
sequenc
particularli
within
rbd
construct
three
plasmid
vaccin
encod
fulllength
membraneanchor
spike
transmembranedelet
spike
contain
entir
ectodomain
subunit
three
plasmid
deliv
intramuscularli
needl
syring
follow
electropor
two
protein
subunit
vaccin
includ
deliv
intramuscularli
needl
syring
ribi
adjuv
five
candid
vaccin
systemat
evalu
mice
accord
eight
immun
regimen
fig
test
immunogen
vaccin
candid
multipl
merscov
requir
biosafeti
level
develop
pseudotyp
report
viru
neutral
assay
previous
confirm
assay
measur
viral
entri
via
merscov
receptor
demonstr
hek
cell
requir
express
surfac
effici
infect
solubl
antibodi
prevent
infect
supplementari
fig
mice
prime
either
protein
twice
dna
boost
protein
gener
highest
neutral
antibodi
nab
titr
among
group
fig
fulllength
dna
regimen
induc
significantli
higher
antibodi
respons
truncat
dna
regimen
antibodi
titr
tend
either
low
undetect
first
dose
dna
boost
immun
protein
two
dose
protein
achiev
neutral
titer
inhibitori
concentr
near
dnaprotein
regimen
three
eight
vaccin
dna
protein
protein
carri
forward
detail
evalu
gave
low
product
yield
transfect
hek
cell
evalu
immun
sera
week
final
boost
three
regimen
test
panel
eight
pseudovirus
found
gener
equal
robust
nab
titr
strain
fig
sequenc
homolog
across
strain
supplementari
fig
like
account
breadth
neutral
sarscov
pseudoviru
neutral
sera
immun
mice
pseudoviru
neutral
result
compar
live
viru
microneutr
assay
strain
genbank
id
pseudoviru
neutral
assay
sensit
neutral
live
viru
although
two
assay
correl
well
one
anoth
basi
rel
magnitud
supplementari
fig
analys
specif
nab
respons
differ
subunit
merscov
spike
glycoprotein
use
sever
method
first
sera
preadsorb
hek
cell
express
transmembraneanchor
version
rbd
fig
supplementari
fig
screen
neutral
fig
sera
preadsorb
untransfect
cell
retain
origin
neutral
activ
neg
control
preimmun
sera
show
capac
viru
neutral
fulllength
spiketransfect
cell
adsorb
virtual
neutral
activ
immun
sera
three
vaccin
group
rbd
express
cell
membran
adsorb
half
neutral
activ
protein
group
suggest
possibl
conform
rbd
present
fulllength
spike
truncat
version
may
differ
adsorpt
also
remov
neutral
activ
protein
group
neutral
capac
two
dnaprim
group
contrast
deplet
neutral
activ
group
except
slightli
mice
vaccin
dna
alon
like
express
cell
result
rearrang
postfus
conform
therefor
neutral
epitop
present
prefus
structur
would
avail
adsorpt
flow
cytometr
analysi
serum
bound
cell
express
differ
spike
subunit
gave
consist
result
supplementari
fig
protein
competit
neutral
assay
recapitul
find
spiketransfect
cell
adsorpt
assay
fig
competit
solubl
rbd
supplementari
fig
reduc
immun
sera
neutral
activ
protein
vaccin
group
seen
cell
adsorpt
assay
solubl
protein
remov
neutral
activ
sera
three
vaccin
group
although
higher
degre
mice
immun
protein
compar
group
prime
dna
solubl
supplementari
fig
impact
serum
neutral
capac
fulllength
spike
use
competitor
could
express
solubl
form
overal
data
indic
serum
neutral
activ
proteinonli
immun
group
direct
primarili
rbd
dnaonli
proteininduc
immun
sera
complex
half
neutral
activ
direct
howev
residu
activ
absorb
compet
conclus
known
adsorb
compet
sera
howev
like
express
protein
postfus
conform
state
sera
also
analys
qualiti
humor
respons
induc
differ
immun
regimen
found
elicit
differ
igg
subclass
respons
pattern
supplementari
fig
b
dna
immun
induc
respons
geometr
mean
titr
gmt
ratio
protein
immun
gener
respons
gmt
ratio
igg
subclass
respons
pattern
appear
determin
prime
immun
dna
protein
boost
regimen
induc
similar
pattern
magnitud
polar
dnaonli
regimen
subclass
respons
respect
reflect
helper
cell
helper
cell
bias
immun
respons
pattern
respons
elicit
dnacontain
regimen
like
due
induct
cell
modul
tcell
monophosphoryl
lipid
abas
ribi
adjuv
suffici
influenc
igg
subclass
polar
toward
phenotyp
would
thu
compar
prime
protein
dna
prime
gener
helper
respons
gener
associ
effect
control
viral
infect
sought
investig
humor
respons
protein
vaccin
isol
character
monoclon
antibodi
mab
differ
specif
hybridoma
gener
dnaprim
proteinboost
mice
screen
bind
rbd
domain
final
round
hybridoma
screen
gener
subclon
supplementari
fig
four
select
addit
character
basi
bind
specif
neutral
potenc
fig
tabl
supplementari
fig
four
mab
demonstr
use
immunofluoresc
bind
live
viru
emc
strain
infect
cell
supplementari
fig
bound
rbd
within
subunit
mab
also
specif
howev
bound
outsid
rbd
bound
subunit
fig
although
potent
rbdspecif
mab
tabl
uniqu
compar
report
mab
abil
neutral
viru
despit
target
epitop
outsid
rbd
solubl
protein
competit
neutral
result
consist
bind
assay
result
supplementari
fig
neutral
diminish
presenc
rbd
compet
activ
abrog
high
concentr
although
two
potent
neutral
rbd
neutral
profil
differ
mab
neutral
test
panel
eight
pseudotyp
report
virus
fig
notabl
unabl
neutral
strain
genbank
id
merscov
supplementari
fig
differ
strain
aspart
acid
glycin
substitut
residu
render
resist
still
suscept
neutral
find
recapitul
pseudotyp
viru
neutral
assay
neutral
activ
wildtyp
ablat
introduct
mutat
supplementari
fig
contrast
neutral
virus
irrespect
aminoacid
chang
posit
addit
rbd
mutat
abrog
bind
use
enzymelink
immunosorb
assay
elisa
affect
bind
fig
provid
atomiclevel
understand
neutral
activ
antibodi
crystal
fab
complex
rbd
fig
b
supplementari
tabl
supplementari
fig
addit
unbound
structur
rbd
determin
fig
found
nearli
ident
rbd
emc
strain
genbank
id
either
complex
ref
one
aminoacid
differ
rbd
supplementari
fig
antibodi
form
direct
contact
receptorbind
motif
rbd
heavychaininteract
region
overlap
contact
region
mer
rbd
human
defin
ref
rbd
residu
bind
conserv
glycan
bound
cdr
cdr
within
paratop
fig
mutat
residu
abrog
abil
bind
fig
e
neutral
viru
supplementari
fig
addit
viru
neutral
escap
analysi
demonstr
anoth
residu
within
epitop
critic
neutral
activ
emc
strain
merscov
escap
neutral
serin
posit
mutat
either
prolin
tryptophan
introduct
prolin
posit
remov
two
hydrogen
bond
antibodi
fig
supplementari
tabl
success
prolin
prolin
nativ
rbd
predict
alter
sidechain
orient
adjac
residu
like
affect
interact
mutat
bulki
tryptophan
side
chain
would
caus
direct
clash
cdr
preclud
bind
fig
although
also
target
rbd
neutral
merscov
differ
mechan
sitedirect
mutagenesi
competitionbind
studi
indic
make
contact
rbd
oppos
side
bind
site
around
residu
bind
studi
also
show
bind
rbd
time
supplementari
fig
suggest
potenti
addit
neutral
effect
differ
point
contact
made
merscov
rbd
analog
mab
specif
sarscov
rbd
supplementari
fig
suggest
converg
mechan
neutral
furthermor
data
elucid
mechan
viru
neutral
involv
disrupt
bind
ntermin
end
merscov
rbd
host
receptor
eight
vaccin
regimen
test
mice
three
immunogen
taken
forward
evalu
nhp
fig
compar
mice
nhp
prime
either
protein
plu
aluminium
phosphat
adjuv
dna
follow
electropor
boost
protein
plu
adjuv
gener
highest
nab
titr
measur
pseudotyp
viru
neutral
assay
compar
dnaonli
group
fig
group
initi
low
antibodi
titr
prime
increas
boost
neutral
titer
final
boost
higher
mice
nhp
could
differ
anim
model
vaccin
dose
adjuv
use
two
studi
antibodi
titr
remain
high
howev
post
boost
persist
higher
level
group
microneutr
assay
merscov
strain
compar
pseudotyp
neutral
assay
demonstr
similar
result
sera
two
group
immun
dna
bound
epitop
recogn
four
previous
character
murin
antibodi
supplementari
fig
sera
nhp
immun
protein
alon
howev
block
mab
target
rbd
nonrbd
subunit
subunit
immun
nhp
challeng
strain
merscov
week
post
boost
demonstr
earlier
diminish
peak
lung
infiltr
compar
unvaccin
nhp
fig
immun
protein
protein
result
respect
four
sixfold
reduct
peak
proport
volum
pulmonari
consolid
fig
demonstr
use
highresolut
comput
tomographi
ct
fig
supplementari
fig
analys
previous
test
method
lung
nhp
immun
protein
experienc
lower
peak
volum
pulmonari
diseas
protein
group
clear
pulmonari
infiltr
rapidli
three
group
exhibit
boost
igg
antibodi
viru
neutral
titr
challeng
greater
magnitud
rise
titr
observ
unvaccin
group
although
viru
isol
could
consist
obtain
oral
nasopharyng
tracheal
swab
three
challeng
group
igg
neutral
antibodi
detect
week
challeng
unvaccin
group
boost
vaccin
group
supplementari
fig
b
suggest
viral
antigen
produc
infect
pre
postchalleng
differ
vaccin
unvaccin
nhp
observ
clinic
symptom
laboratori
test
valu
histopatholog
paramet
addit
statist
signific
correl
neutral
antibodi
either
day
challeng
peak
week
last
boost
percentag
abnorm
lung
volum
supplementari
fig
summari
develop
dna
express
vector
solubl
protein
immunogen
elicit
crossreact
neutral
antibodi
known
circul
strain
merscov
specif
immun
dna
express
fulllength
spike
plu
electropor
follow
subunit
protein
yield
potent
neutral
mab
mice
nhp
current
immun
strategi
first
induc
merscovneutr
antibodi
target
multipl
epitop
within
outsid
rbd
may
potenti
improv
immunogen
reduc
likelihood
escap
mutat
context
merscov
also
first
time
combin
dna
protein
immunogen
test
anim
model
first
time
immun
regimen
evalu
demonstr
protect
nhp
caveat
mention
recent
two
anim
challeng
model
report
immun
mice
first
mice
transduc
adenovir
vector
express
human
ref
model
zhao
et
al
abl
demonstr
product
infect
challeng
mice
reduct
viral
titr
lung
mice
immun
venezuela
equin
enceph
replicon
particl
express
merscov
spike
glycoprotein
although
repres
advanc
develop
viabl
anim
model
merscov
transduc
mice
still
limit
relev
human
infect
inconsist
express
transduc
protein
case
human
potenti
sustain
transgen
lethal
mous
model
report
agraw
et
al
demonstr
product
dissemin
merscov
infect
viral
recoveri
lung
rhesu
macaqu
demonstr
overt
clinic
diseas
howev
develop
lower
respiratori
tract
pulmonari
infiltr
challeng
merscov
virolog
sampl
lung
nhp
complic
bronchoalveolar
lavag
although
increas
yield
viru
recoveri
would
like
confound
radiolog
find
addit
strain
use
challeng
nhp
may
less
virul
emc
strain
use
challeng
studi
rhesu
macaqu
nonetheless
pattern
pulmonari
diseas
highresolut
ct
differ
significantli
vaccin
unvaccin
nhp
mice
induc
mab
crossreact
multipl
merscov
strain
direct
rbd
spike
epitop
outsid
rbd
subunit
cocryst
structur
analysi
escap
mutat
provid
mechanist
explan
neutral
rbddirect
neutral
antibodi
rbdspecif
antibodi
isol
compar
other
report
literatur
particularli
isol
human
antibodi
phage
howev
target
differ
epitop
approxim
potent
neutral
capac
previous
report
appear
highli
novel
epitop
recognit
show
epitop
overlap
mab
loop
region
howev
ad
sensit
mutat
posit
seen
thu
highlight
differ
respect
epitop
compar
protein
alon
dna
protein
boost
immun
yield
function
divers
repertoir
neutral
antibodi
also
gener
immun
respons
dnaprim
regimen
also
offer
greater
earlier
protect
radiograph
defin
pneumonia
challeng
nhp
basi
earlier
clearanc
lung
infiltr
suggest
potenti
contribut
effector
cell
elicit
dna
immun
thu
proteinonli
merscov
vaccin
may
simpler
approach
potenti
advantag
includ
dna
prime
includ
improv
potenc
durabl
immun
context
sarscov
previous
shown
mice
dna
prime
coupl
inactiv
viru
boost
enhanc
cellular
humor
modif
boost
interv
addit
improv
magnitud
function
properti
antibodi
respons
may
also
achiev
case
convent
influenza
although
studi
would
need
confirm
merscov
immunogen
present
spike
trimer
nativ
conform
surfac
transduc
cell
dna
immun
may
contribut
gener
divers
set
antibodi
could
neutral
merscov
target
rbd
also
epitop
outsid
rbd
may
capabl
rbdspecif
antibodi
prevent
viral
escap
addit
provid
broader
array
function
antibodi
respons
nonrbddirect
antibodi
may
aid
solv
trimer
spike
glycoprotein
structur
target
quarternari
epitop
stabil
prefus
conform
structur
inform
nativ
pretrigg
glycoprotein
trimer
import
inform
secondgener
immunogen
design
respiratori
syncyti
experiment
vaccin
yield
mab
provid
inform
key
viral
structur
mechan
neutral
guid
improv
merscov
immunogen
similar
iter
cycl
rapid
empir
antigen
design
antibodi
discoveri
develop
reagent
assay
character
immunogen
differ
anim
model
may
also
applic
emerg
viral
anim
experi
carri
complianc
pertin
us
nation
institut
health
regul
polici
nation
institut
health
nation
institut
allergi
infecti
diseas
vaccin
research
center
anim
care
use
committe
review
approv
anim
experi
construct
dna
vaccin
merscov
strain
spike
strain
genbank
id
two
truncat
version
fig
aminoacid
sequenc
obtain
genbank
reversetransl
codonoptim
human
cell
express
seventyfivebas
pair
bp
oligonucleotid
set
twentyfivebas
pair
overlap
synthes
gelpurifi
oligonucleotid
assembl
dna
fragment
use
pfu
turbo
hotstart
dna
polymeras
stratagen
la
jolla
ca
gradient
anneal
temperatur
dna
fragment
clone
pcrblunt
iitopo
vector
invitrogen
carlsbad
ca
sequenc
clone
mammalian
express
vector
ref
truncat
domainswap
mutant
synthes
pcr
use
fulllength
spike
templat
fig
clone
sequenceconfirm
plasmid
protein
express
transfect
vector
encod
correspond
gene
cell
line
transfect
cell
cultur
supernat
collect
purifi
histrap
hp
hiload
superdex
column
ge
healthcar
piscataway
nj
usa
synthes
cdna
encod
spike
use
quikchang
xl
kit
stratagen
introduc
diverg
amino
acid
parent
spike
strain
predict
translat
sequenc
strain
genbank
id
genbank
id
genbank
id
emc
genbank
id
genbank
id
genbank
id
munich
genbank
id
construct
confirm
use
sequenc
hek
cell
obtain
atcc
manassa
va
usa
cell
provid
dr
deborah
r
taylor
us
fda
cell
line
cultur
dmem
bsa
mm
glutamin
penicillinstreptomycin
incub
contain
overal
hek
cell
aliquot
plate
cotransfect
three
plasmid
packag
plasmid
transduc
plasmid
phr
cmvluc
cmvrmerscov
plasmid
calcium
phosphat
transfect
reagent
invitrogen
overnight
incub
medium
replac
fresh
fortyeight
hour
later
supernat
collect
filter
aliquot
frozen
pseudoviru
titrat
first
plate
cell
per
well
whiteblack
isopl
perkinelm
waltham
cultur
overnight
medium
remov
twofold
serial
dilut
pseudoviru
ad
cell
h
incub
fresh
media
ad
cell
lyse
h
later
luciferas
substrat
promega
madison
wi
ad
well
luciferas
activ
measur
accord
rel
luciferas
unit
cp
count
per
second
use
microbeta
luminesc
counter
perkinelm
fulllength
aminoacid
sequenc
spike
merscov
strain
munich
emc
align
use
mafft
linsi
version
http
trexuqamca
phylogenet
tree
gener
averag
linkag
upgma
method
phylogenet
tree
drawn
itol
server
http
itolembld
femal
balbcj
mice
age
week
jackson
laboratori
bar
harbor
immun
accord
sever
regimen
dna
ii
protein
iii
protein
within
dnaonli
categori
three
group
mice
inject
plasmid
dna
encod
either
merscov
fulllength
spike
group
spike
delet
transmembran
unit
group
group
intramuscularli
follow
electropor
manufacturerrecommend
set
agilepuls
system
harvard
apparatu
holliston
week
group
ii
inject
twice
plasmid
dna
either
encod
merscov
fulllength
spike
group
group
group
week
describ
boost
either
merscov
group
group
protein
plu
ribi
adjuv
sigmaaldrich
st
loui
mo
week
proteinonli
group
iii
inject
twice
merscov
group
protein
group
plu
ribi
adjuv
week
twenti
microgram
plasmid
dna
total
volum
pb
protein
pb
mix
equal
volum
ribi
adjuv
compris
dna
protein
immun
respect
two
week
inject
sera
collect
measur
antibodi
respons
eighteen
femal
male
indian
rhesu
macaqu
macaca
mulatta
weigh
kg
mean
age
year
randomli
assign
three
group
accord
sex
weight
immun
accord
one
three
differ
vaccin
regimen
dna
protein
protein
sampl
size
base
convent
dnaonli
group
six
nhp
inject
mg
plasmid
dna
encod
merscov
fulllength
spike
week
six
nhp
protein
group
inject
mg
plasmid
dna
encod
merscov
fulllength
spike
week
boost
merscov
protein
adjuv
brenntag
biosector
frederikssund
denmark
week
six
nhp
proteinonli
group
inject
merscov
protein
adjuv
week
plasmid
dna
given
intramuscularli
follow
electropor
protein
inject
intramuscularli
sera
collect
week
inject
everi
week
thereaft
week
eighteen
indian
rhesu
unvaccin
six
vaccin
protein
six
vaccin
challeng
strain
merscov
genbank
id
approv
highcontain
facil
week
last
immun
nhp
inocul
intratrach
ml
pfu
via
laryngoscop
lubric
cathet
viru
challeng
inoculum
assay
determin
deliv
dose
deliv
dose
pfu
cohort
respect
nhp
monitor
clinic
laboratori
radiolog
paramet
day
postchalleng
day
nhp
underw
necropsi
viru
challeng
nhp
underw
chest
ct
petct
gemini
tof
imag
philip
andov
ct
imag
evalu
analys
two
blind
boardcertifi
radiologist
lung
patholog
assess
longitudin
use
publish
pulmonari
imag
analysi
imag
segment
method
use
determin
lung
region
interest
follow
machinelearn
algorithm
random
forest
assess
tissu
class
normal
abnorm
pixel
within
region
interest
quantifi
diseas
sever
base
quantit
total
lung
capac
patholog
volum
present
proport
ratio
patholog
volum
total
lung
volum
random
forest
algorithm
tune
accord
ground
glass
opac
consolid
pattern
two
pattern
constitut
patholog
format
previou
experi
cell
cell
per
well
plate
whiteblack
isopl
perkinelm
day
infect
serum
serial
dilut
mix
differ
strain
titrat
pseudoviru
incub
min
min
room
temperatur
ad
cell
triplic
follow
h
incub
well
replenish
fresh
media
cell
lyse
h
later
luciferas
activ
measur
neutral
titr
calcul
individu
mous
serum
sampl
twofold
dilut
heatinactiv
group
sera
test
presenc
antibodi
neutral
infect
merscov
strain
vero
cell
monolay
use
four
well
per
dilut
plate
viral
cytopath
effect
read
day
serum
dilut
complet
prevent
cytopath
effect
well
calcul
use
hek
cell
transfect
plasmid
express
merscov
fulllength
rbdhatm
spike
rbd
influenza
haemagglutinin
transmembran
domain
twentyfour
hour
later
cell
detach
mm
edta
pb
stain
vivid
viabil
dye
invitrogen
cell
stain
mous
sera
dilut
cell
subsequ
stain
goat
antimous
iggphycoerythrin
santa
cruz
biotechnolog
santa
cruz
ca
sort
lsr
bd
bioscienc
san
jose
ca
data
analys
use
flowjo
softwar
tree
star
inc
ashland
elisa
plate
coat
merscov
protein
pb
overnight
standard
wash
block
plate
incub
serial
dilut
mous
sera
antimous
peroxidas
conjug
jackson
laboratori
use
secondari
antibodi
tmb
kpl
gaithersburg
md
use
substrat
detect
merscov
antibodi
respons
end
point
titr
calcul
highest
serum
dilut
gave
optic
densiti
exceed
five
time
background
read
sixti
per
cent
confluent
whovero
cell
glass
coverslip
infect
merscov
pfu
per
cell
hour
post
infect
cell
fix
permeabil
methanol
oc
step
occur
condit
use
protocol
approv
institut
biosafeti
committe
vanderbilt
univers
cdc
cell
rehydr
pb
block
pb
bsa
rins
wash
pb
bsa
nonidet
cell
incub
primari
antibodi
indic
dilut
min
rins
wash
min
incub
secondari
antibodi
goat
molecular
probe
min
cell
wash
min
wash
pb
distil
water
coverslip
mount
aquapolymount
polysci
visual
use
microscopi
nikon
eclips
widefield
fluoresc
microscop
use
oilimmers
differenti
interfer
contrast
filter
imag
merg
assembl
use
nikon
element
imagej
adob
photoshop
infect
mockinfect
cell
process
parallel
mice
group
boost
intraven
addit
three
day
later
splenocyt
harvest
fuse
myeloma
cell
atcc
use
polyethylen
glycol
peg
wv
sigmaaldrich
accord
standard
method
cell
cultur
screen
rpmi
complet
medium
contain
fc
hypoxanthin
aminopterin
thymidin
sigmaaldrich
supernat
result
hybridoma
screen
bind
use
elisa
mer
rbd
well
neutral
activ
subclon
gener
limit
dilut
three
round
screen
subclon
stabl
antibodyproduc
clone
isol
adapt
hybridomaserumfre
medium
life
technolog
corp
grand
island
ny
usa
supernat
collect
select
hybridoma
clone
purifi
protein
asepharos
column
ge
healthcar
mab
isotyp
pierc
rapid
isotyp
kit
bind
kinet
merscov
molecul
antibodi
carri
use
octet
instrument
assay
agit
set
rpm
pb
buffer
supplement
bsa
per
well
perform
solid
black
tiltedbottom
plate
geiger
bioon
mous
antibodi
use
load
antimous
igg
fc
captur
probe
captur
level
nm
biosensor
tip
equilibr
bsa
buffer
bind
assess
merscov
molecul
follow
dissoci
humanfcmerscov
chimer
molecul
use
load
antihuman
igg
fc
captur
probe
bind
fab
assess
data
analysi
curv
fit
carri
octet
softwar
v
construct
encod
rbd
residu
ctermin
cleavag
site
purif
tag
produc
cell
protein
purifi
use
ninta
affin
chromatographi
fab
prepar
use
pierc
mous
fab
kit
rbd
molecul
mix
fab
molar
ratio
allow
sit
min
room
temperatur
protein
purifi
use
size
exclus
chromatographi
superdex
concentr
mg
crystal
screen
carri
use
mosquito
crystal
robot
use
hang
drop
vapour
diffus
method
oc
mix
protein
complex
reservoir
solut
follow
manual
optim
rbd
crystal
obtain
use
reservoir
solut
trishcl
ph
mpd
polyethylen
glycol
peg
crystal
form
fab
rbd
complex
grown
sodium
acet
ph
mm
sodium
chlorid
peg
peg
crystal
cryocool
liquid
nitrogen
use
mother
liquor
contain
ethylen
glycol
cryoprotect
crystal
form
fab
rbd
grown
sodium
cacodyl
ph
mm
magnesium
acet
peg
use
butanediol
cryoprotect
data
collect
wavelength
sercat
beamlin
advanc
photon
sourc
argonn
nation
laboratori
diffract
data
process
structur
solv
molecular
replac
use
iter
model
build
refin
perform
respect
rbd
crystal
solut
obtain
use
pdb
id
ref
molecul
b
search
model
two
crystal
form
rbd
complex
solut
obtain
use
pdb
id
molecul
b
search
model
rbd
pdb
id
ref
search
model
fab
variabl
domain
mous
constant
region
fab
pdb
id
search
model
fab
constant
domain
crystal
form
two
complex
obtain
per
asymmetr
unit
crossvalid
test
set
use
data
use
assess
model
refin
process
structur
model
valid
carri
use
rbd
model
refin
final
rfactor
valu
rfree
valu
rbd
crystal
form
gave
structur
model
final
rfactor
valu
rfree
valu
rbd
crystal
form
gave
structur
model
final
rfactor
rfree
valu
structur
residu
favour
region
ramachandran
plot
whovero
cell
vero
provid
ralph
baric
univers
north
carolinachapel
hill
maintain
dulbecco
modifi
eagl
medium
invitrogen
contain
fb
supplement
penicillin
streptomycin
amphotericin
b
merscov
emc
strain
gener
infecti
clone
ralph
propag
assess
use
plaqu
assay
vero
cell
cell
viru
incub
viral
studi
perform
certifi
laboratori
exclus
within
biolog
safeti
cabinet
use
protocol
safe
studi
mainten
transfer
review
approv
institut
biosafeti
committe
vanderbilt
univers
start
concentr
mab
serial
dilut
fivefold
mix
equal
amount
viru
total
six
time
mixtur
incub
oc
min
mixtur
use
inocul
vero
cell
monolay
sixwel
plate
duplic
follow
incub
cell
overlaid
complet
media
plu
agar
plaqu
visual
count
h
post
infect
amount
infecti
viru
presenc
mab
concentr
calcul
graph
mab
ad
flask
vero
cell
ml
dmem
contain
serum
follow
merscov
multipl
infect
pfu
two
day
later
mab
supernat
previou
infect
ad
new
flask
vero
cell
three
separ
lineag
carri
parallel
increas
amount
mab
passag
follow
fifth
passag
supernat
remov
aliquot
frozen
thaw
titr
use
plaqu
assay
presenc
absenc
mab
ten
plaqu
well
mab
lineag
pick
use
inocul
flask
day
supernat
remov
aliquot
frozen
cell
lyse
use
trizol
reagent
life
technolog
corp
accord
manufactur
instruct
frozen
total
cellular
rna
extract
lysat
infect
mabresist
plaqu
clone
subject
merscov
spike
gene
amplifi
two
overlap
amplicon
use
primer
cctcatctgaaggattcc
aatcattgtcctgctggc
caccaatagtgtttgccc
cataccaggttttggagg
gatggtcctaccgaacat
tatacgcagagctatagact
amplicon
sequenc
give
complet
gene
coverag
result
sequenc
assembl
compar
expect
theoret
sequenc
merscov
spike
calcul
gmt
confid
interv
antibodi
titr
mean
se
calcul
data
p
valu
calcul
twotail
unpair
nonparametr
test
use
prism
softwar
version
graphpad
la
jolla
ca
statist
signific
differ
met
threshold
statist
variat
within
data
set
repres
standard
error
figur
pearson
correl
coeffici
associ
p
valu
calcul
use
prism
softwar
varianc
gener
similar
justifi
use
nonparametr
statist
test
cite
articl
wang
l
et
al
evalu
candid
vaccin
approach
merscov
nat
commun
doi
